A Safety, Pharmacokinetics and Pharmacodynamics Study of RO6811135 in Patients With Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
This randomized, double-blind, placebo-controlled, multiple ascending dose study will
evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO6811135 in
patients with type 2 diabetes mellitus. Patients will be randomized to receive either
RO6811135 or placebo daily for 2 weeks, with a follow-up examination 2 to 3 weeks after the
last dose of study drug.